89971-01-7

Basic information

• Product Name: 2-(2,3-Dimethoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
• Synonyms: 2-(2,3-Dimethoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
• CAS NO: 89971-01-7
• Molecular Formula: C17H14 O6
• Molecular Weight: 0
• Mol File: 89971-01-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 547.7°C at 760 mmHg
• Flash Point: 205.1°C
• Appearance: /
• Density: 1.402g/cm³
• Vapor Pressure: 1.31E-12mmHg at 25°C
• Refractive Index: 1.645
• CAS DataBase Reference: 2-(2,3-Dimethoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,3-Dimethoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one(89971-01-7)
• EPA Substance Registry System: 2-(2,3-Dimethoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one(89971-01-7)

Safety Data

• Hazardous Substances Data: 89971-01-7(Hazardous Substances Data)

Usage

Classification

Flavonoid

Natural sources

Citrus fruits and other plants

+ Antioxidant

Reduces oxidative stress and inflammation in various disease states.

+ Anti-inflammatory

Decreases inflammation in conditions such as chronic venous insufficiency, hemorrhoids, and lymphedema.

+ Improves venous tone

Enhances the function of the veins and reduces symptoms of vascular conditions.

+ Reduces capillary permeability

Decreases the leakage of fluid and waste products from blood vessels, which can lead to swelling and other symptoms.

Medicinal applications

Treatment of vascular conditions, including chronic venous insufficiency, hemorrhoids, and lymphedema.

InChI:InChI=1/C17H14O6/c1-21-13-5-3-4-10(17(13)22-2)14-8-12(20)16-11(19)6-9(18)7-15(16)23-14/h3-8,18-19H,1-2H3

Upstream product

• 110865-03-7 2-chloro-1-(2,4,6-trihydroxyphenyl)ethan-1-one 
• 86-51-1 2,3-dimethyoxybenzaldehyde 
• 108-73-6 3,5-dihydroxyphenol 

Relevant articles and documents

Inhibitory effect of flavonoids on human glutaminyl cyclase

Glutaminyl cyclase (QC) plays an important role in the pathogenesis of Alzheimer's disease (AD) and can be a potential target for the development of novel anti-AD agents. However, the study of QC inhibitors are still less. Here, phenol-4′ (R1-), C5-OH (R2-) and C7-OH (R3-) modified apigenin derivatives were synthesized as a new class of human QC (hQC) inhibitors. The efficacy investigation of these compounds was performed by spectrophotometric assessment and the structure-activity relationship (SAR) was evaluated. Molecular docking was also carried out to analyze the binding mode of the synthesized flavonoid to the active site of hQC.